Yuyun Yan
Guangzhou, 511436, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Discovery of novel 8-hydroxyquinoline derivatives as NLRP3 inflammasome inhibitors with therapeutic potential for inflammatory bowel disease.
Journal: European journal of medicinal chemistry
Published: April 24, 2025
Discovery, synthesis, and biological mechanism evaluation of novel quinoline derivatives as potent NLRP3 inhibitors.
Journal: European journal of medicinal chemistry
Published: January 06, 2025
Chlorquinaldol Alleviates Lung Fibrosis in Mice by Inhibiting Fibroblast Activation through Targeting Methionine Synthase Reductase.
Journal: ACS central science
Published: May 18, 2024
Design, synthesis and biological evaluation of tanshinone IIA derivatives as NLRP3 inflammasome inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: October 17, 2023
Discovery of a dual-acting inhibitor of interleukin-1β and STATs for the treatment of inflammatory bowel disease.
Journal: RSC medicinal chemistry
Published: August 30, 2023
Discovery of a selective NLRP3-targeting compound with therapeutic activity in MSU-induced peritonitis and DSS-induced acute intestinal inflammation.
Journal: Cellular and molecular life sciences : CMLS
Published: April 27, 2023
Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis.
Journal: International immunopharmacology
Published: September 06, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026